Real-world U.S. outcomes of anti-VEGF therapy in diabetic macular edema

Related

• 

  Progression of diabetic retinopathy in patients treated with 0.2 μg/day

  Raymond Iezzi, MD, MS

  Updates from the Field

  2017

• 

  Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

  Caroline Baumal, MD, FASRS

  Updates from the Field

  2021

• 

  AMD Neovascular Expert Panel

  Robert L. Avery, MD

  Nizar S Abdelfattah, M.D.

  Nancy M. Holekamp, MD, FASRS

  Peter K. Kaiser, MD FASRS

  Pravin U. Dugel, MD

  Annual Meeting Talks

  2016